Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tempus SCLC Observational Study: A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays

NCT05257551 is registered in ClinicalTrials.gov with Tempus AI as lead sponsor.

NCT NCT05257551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05257551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tempus SCLC Observational Study: A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays
Lead sponsor
Tempus AI
Phase
Observational
Overall status
Recruiting
Start date
July 13, 2022
Completion date
March 31, 2029
Enrollment
200 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer